Segment & Geographic Data
API & CSV Delivery
Hutchmed China Limited's Business Segments
Hutchmed China Limited's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
2
Largest Segment
Oncology or Immunology Segment
Total Revenue
$ 549
Regions Reported
1
Annual Results
Revenue Share by Reportable Segment - FY2025
- Oncology or Immunology Segment52.1%
- Other Ventures segment47.9%
Revenue by Reportable Segment - FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Oncology or Immunology Segment | $ 286 | 52.1% |
| Other Ventures segment | $ 263 | 47.9% |
Revenue Share by Country - FY2025
- CN74.3%
Revenue by Geographic Country - FY2025
| Country | Revenue (Millions) | % of Total |
|---|---|---|
| CN | $ 407 | 74.3% |
Revenue by Product & Service Category - FY2025
- Product71.7%
- Goods Distribution47.9%
- Marketed Products18.3%
- Other Collaboration Royalties Revenue12.5%
- Commercialization Services8.3%
- Manufacturing Supply Invoiced Marketed Products Sales8.2%
- Revenue From Royalties of Marketed Products8.1%
- License and Collaborations Manufacturing Supply5.7%
- Manufacturing Supply Allocated From Upfront Payment5.7%
- Collaboration Research and Development5.1%
- Services Collaboration Research and Development From Upfront Payment3.2%
- Other Collaboration Licensing Revenue2.2%
- Licensing From Upfront Payment0.3%
- Research and Development Services0.2%
Revenue by Product & Service Category - FY2025
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 393 | 71.7% |
| Goods Distribution | $ 263 | 47.9% |
| Marketed Products | $ 101 | 18.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
11 more categories available
Sign in to unlock the full Hutchmed China Limited dataset.
Description of Hutchmed China Limited
Hutchmed China Limited, commonly known as Hutchison China MediTech, is a biopharmaceutical company headquartered in Hong Kong, China. The company is primarily focused on discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and other medical conditions.
Hutchmed was established in 2000 as a subsidiary of Hutchison Whampoa Limited, a multinational conglomerate. In 2016, Hutchmed was spun off as an independent, publicly traded company listed on the Hong Kong Stock Exchange, raising approximately $100 million in the process.
The company's oncology portfolio consists of several late-stage clinical programs, including sulfatinib, a selective inhibitor of vascular endothelial growth factor receptor (VEGFR), which is being developed for the treatment of advanced neuroendocrine tumors (NETs) and biliary tract cancer (BTC). Hutchmed also has several non-oncology programs, including a late-stage clinical program for the treatment of hyperuricemia and gout.
With a focus on precision medicine, the company aims to develop targeted therapies that can more effectively treat patients while reducing the risk of side effects. Hutchmed has established collaborations with leading academic institutions and pharmaceutical companies in China and internationally to advance its innovative drug discovery and development programs.
Hutchmed has a strong presence in China and has established a commercial infrastructure to support the launch of new products. The company currently has more than 600 employees, including over 200 scientists and researchers working in its R&D facilities in Shanghai, China.
In addition to its drug discovery and development programs, Hutchmed is committed to supporting cancer patients and their families. The company has launched several patient assistance programs in China to provide financial assistance and emotional support to cancer patients.
Overall, Hutchmed is a leading biopharma company with a strong focus on innovative drug discovery and development programs in oncology and other medical areas. The company's dedication to precision medicine and patient-centered care has made it a significant player in the rapidly growing global biopharmaceutical industry.
Hutchmed was established in 2000 as a subsidiary of Hutchison Whampoa Limited, a multinational conglomerate. In 2016, Hutchmed was spun off as an independent, publicly traded company listed on the Hong Kong Stock Exchange, raising approximately $100 million in the process.
The company's oncology portfolio consists of several late-stage clinical programs, including sulfatinib, a selective inhibitor of vascular endothelial growth factor receptor (VEGFR), which is being developed for the treatment of advanced neuroendocrine tumors (NETs) and biliary tract cancer (BTC). Hutchmed also has several non-oncology programs, including a late-stage clinical program for the treatment of hyperuricemia and gout.
With a focus on precision medicine, the company aims to develop targeted therapies that can more effectively treat patients while reducing the risk of side effects. Hutchmed has established collaborations with leading academic institutions and pharmaceutical companies in China and internationally to advance its innovative drug discovery and development programs.
Hutchmed has a strong presence in China and has established a commercial infrastructure to support the launch of new products. The company currently has more than 600 employees, including over 200 scientists and researchers working in its R&D facilities in Shanghai, China.
In addition to its drug discovery and development programs, Hutchmed is committed to supporting cancer patients and their families. The company has launched several patient assistance programs in China to provide financial assistance and emotional support to cancer patients.
Overall, Hutchmed is a leading biopharma company with a strong focus on innovative drug discovery and development programs in oncology and other medical areas. The company's dedication to precision medicine and patient-centered care has made it a significant player in the rapidly growing global biopharmaceutical industry.
Hutchmed China Limited is a key player in the healthcare sector with a significant focus on oncology. The company operates primarily in two distinct segments:
Segments
1. Drug Discovery and Development:
Hutchmed is engaged in the innovative research and development of novel small molecule targeted therapies aimed at addressing various forms of cancer. The company has cultivated a robust pipeline, showcasing a diverse array of drug candidates that are positioned at different stages of clinical development. This segment is pivotal to the company’s mission, as it leverages cutting-edge scientific principles to discover and develop treatment options that cater to unmet medical needs in oncology.
2. Commercialization of Innovative Anticancer Therapies:
This segment is focused on bringing established anticancer products to market, particularly within China. Hutchmed’s commercialization efforts center around approved therapies that serve specific indications, reflecting the company’s commitment to improving patient outcomes by providing innovative treatment options.
Products and Services
1. Drug Discovery and Development:
Hutchmed’s extensive pipeline is characterized by drug candidates that target critical pathways in cancer progression. Notable candidates include:
- Surufatinib:
An oral small molecule inhibitor targeting multiple receptors, including VEGFR, FGFR, and CSF-1R. Surufatinib is being explored as a treatment for various solid tumors, notably neuroendocrine tumors (NETs), biliary tract cancer, and gastric cancer. Its multifaceted approach to tumor blood supply and support mechanisms positions it as a promising candidate for complex malignancies.
- Fruquintinib:
This oral small molecule selectively inhibits VEGFR1, VEGFR2, and VEGFR3, thereby impairing tumor angiogenesis. Clinical investigations are exploring its efficacy against non-small-cell lung cancer (NSCLC), colorectal cancer, and gastric cancer. Fruquintinib has the potential to alleviate the challenge of treatment-resistant tumors through its targeted action.
- HMPL-689:
Designed as an oral BTK inhibitor, HMPL-689 is being developed for the treatment of various B-cell malignancies, featuring potential applications in conditions such as chronic lymphocytic leukemia (CLL) and other hematological cancers. Its specificity for BTK may provide advantages in reducing off-target effects associated with broader-spectrum therapies.
2. Commercialization of Innovative Anticancer Therapies:
Hutchmed has successfully launched a variety of anticancer therapies in the Chinese market, which exemplify its commitment to providing advanced cancer treatments. The commercially available products include:
- Elunate (Fructoborate Tromethamine Tablets):
This small molecule angiogenesis inhibitor is indicated for the treatment of metastatic colorectal cancer (mCRC). Elunate serves as an integral component of therapeutic regimens for patients, aiming to improve survival and quality of life.
- Sulanda (Sulodexide Capsules):
Classed as a heparinoid compound, Sulanda is used in managing diabetic nephropathy. Its role extends beyond oncologic applications, showcasing Hutchmed’s broader therapeutic interests in chronic conditions that may co-exist with malignancies.
- Anlotinib:
This small molecule multitargeted tyrosine kinase inhibitor is indicated for advanced NSCLC and soft tissue sarcoma (STS). By targeting multiple pathways involved in tumor growth and metastasis, Anlotinib is positioned as a valuable therapeutic option in the oncology market.
- Epitinib:
Serving as an oral EGFR tyrosine kinase inhibitor, Epitinib is specifically aimed at the treatment of NSCLC. Its targeted mechanism acts to inhibit pathways that are often aberrantly activated in cancer, particularly in patients with EGFR mutations.
Additional Services:
Beyond its therapeutic offerings, Hutchmed China Limited also provides a suite of clinical research and non-clinical development services tailored to the needs of other pharmaceutical and biotech entities. These services comprise:
- Clinical Trial Management:
Comprehensive management of clinical trials from design to execution, ensuring adherence to regulatory standards and facilitating successful trial outcomes.
- Regulatory Affairs:
Assistance in navigating complex regulatory frameworks, ensuring that products meet all necessary safety and efficacy standards for approval.
- Data Management:
Implementation of robust data management protocols to ensure integrity, security, and regulatory compliance throughout clinical research processes.
- Pharmacovigilance:
Ongoing monitoring and evaluation of drug safety post-marketing to provide insights that enhance overall therapeutic strategies and patient outcomes.
In summary, Hutchmed China Limited is significantly invested in transforming the oncology landscape through its innovative drug discovery and development efforts, coupled with its commitment to the commercialization of effective therapies. Their extensive product pipeline and critical services underscore their role as a forward-thinking entity in the healthcare sector.
Segments
1. Drug Discovery and Development:
Hutchmed is engaged in the innovative research and development of novel small molecule targeted therapies aimed at addressing various forms of cancer. The company has cultivated a robust pipeline, showcasing a diverse array of drug candidates that are positioned at different stages of clinical development. This segment is pivotal to the company’s mission, as it leverages cutting-edge scientific principles to discover and develop treatment options that cater to unmet medical needs in oncology.
2. Commercialization of Innovative Anticancer Therapies:
This segment is focused on bringing established anticancer products to market, particularly within China. Hutchmed’s commercialization efforts center around approved therapies that serve specific indications, reflecting the company’s commitment to improving patient outcomes by providing innovative treatment options.
Products and Services
1. Drug Discovery and Development:
Hutchmed’s extensive pipeline is characterized by drug candidates that target critical pathways in cancer progression. Notable candidates include:
- Surufatinib:
An oral small molecule inhibitor targeting multiple receptors, including VEGFR, FGFR, and CSF-1R. Surufatinib is being explored as a treatment for various solid tumors, notably neuroendocrine tumors (NETs), biliary tract cancer, and gastric cancer. Its multifaceted approach to tumor blood supply and support mechanisms positions it as a promising candidate for complex malignancies.
- Fruquintinib:
This oral small molecule selectively inhibits VEGFR1, VEGFR2, and VEGFR3, thereby impairing tumor angiogenesis. Clinical investigations are exploring its efficacy against non-small-cell lung cancer (NSCLC), colorectal cancer, and gastric cancer. Fruquintinib has the potential to alleviate the challenge of treatment-resistant tumors through its targeted action.
- HMPL-689:
Designed as an oral BTK inhibitor, HMPL-689 is being developed for the treatment of various B-cell malignancies, featuring potential applications in conditions such as chronic lymphocytic leukemia (CLL) and other hematological cancers. Its specificity for BTK may provide advantages in reducing off-target effects associated with broader-spectrum therapies.
2. Commercialization of Innovative Anticancer Therapies:
Hutchmed has successfully launched a variety of anticancer therapies in the Chinese market, which exemplify its commitment to providing advanced cancer treatments. The commercially available products include:
- Elunate (Fructoborate Tromethamine Tablets):
This small molecule angiogenesis inhibitor is indicated for the treatment of metastatic colorectal cancer (mCRC). Elunate serves as an integral component of therapeutic regimens for patients, aiming to improve survival and quality of life.
- Sulanda (Sulodexide Capsules):
Classed as a heparinoid compound, Sulanda is used in managing diabetic nephropathy. Its role extends beyond oncologic applications, showcasing Hutchmed’s broader therapeutic interests in chronic conditions that may co-exist with malignancies.
- Anlotinib:
This small molecule multitargeted tyrosine kinase inhibitor is indicated for advanced NSCLC and soft tissue sarcoma (STS). By targeting multiple pathways involved in tumor growth and metastasis, Anlotinib is positioned as a valuable therapeutic option in the oncology market.
- Epitinib:
Serving as an oral EGFR tyrosine kinase inhibitor, Epitinib is specifically aimed at the treatment of NSCLC. Its targeted mechanism acts to inhibit pathways that are often aberrantly activated in cancer, particularly in patients with EGFR mutations.
Additional Services:
Beyond its therapeutic offerings, Hutchmed China Limited also provides a suite of clinical research and non-clinical development services tailored to the needs of other pharmaceutical and biotech entities. These services comprise:
- Clinical Trial Management:
Comprehensive management of clinical trials from design to execution, ensuring adherence to regulatory standards and facilitating successful trial outcomes.
- Regulatory Affairs:
Assistance in navigating complex regulatory frameworks, ensuring that products meet all necessary safety and efficacy standards for approval.
- Data Management:
Implementation of robust data management protocols to ensure integrity, security, and regulatory compliance throughout clinical research processes.
- Pharmacovigilance:
Ongoing monitoring and evaluation of drug safety post-marketing to provide insights that enhance overall therapeutic strategies and patient outcomes.
In summary, Hutchmed China Limited is significantly invested in transforming the oncology landscape through its innovative drug discovery and development efforts, coupled with its commitment to the commercialization of effective therapies. Their extensive product pipeline and critical services underscore their role as a forward-thinking entity in the healthcare sector.